TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) is now available.
Shandong Boan Biotechnology Co., Ltd. announced the marketing approval of its aflibercept intravitreous injection, Boyoujing®, by China’s National Medical Products Administration. This biosimilar to EYLEA® is indicated for treating neovascular age-related macular degeneration and diabetic macular edema. The company will collaborate with Ocumension Therapeutics to commercialize Boyoujing® in China, leveraging Ocumension’s extensive network and expertise in ophthalmic drugs. The approval and commercialization of Boyoujing® are expected to enhance patient access to effective treatments and drive the company’s long-term growth in the rapidly expanding market for anti-angiogenic ophthalmic therapies in China.
More about Shandong Boan Biotechnology Company., Limited. Class H
Shandong Boan Biotechnology Co., Ltd. is a biotechnology company based in China, focusing on the development and commercialization of biosimilar products. The company operates in the pharmaceutical industry, with a market focus on ophthalmic drugs, particularly for treating retinal diseases such as age-related macular degeneration and diabetic macular edema.
Average Trading Volume: 8,942,818
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.5B
See more data about 6955 stock on TipRanks’ Stock Analysis page.